(Q48326604)

English

Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

neuropathic pain

0 references

1 reference

based on heuristic

inferred from title

peripheral neuropathy

1 reference

based on heuristic

inferred from title

author name string

J Satoh

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

S Yagihashi

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

M Baba

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

M Suzuki

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

A Arakawa

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

T Yoshiyama

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

S Shoji

7

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

publication date

1 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

Diabetic Medicine

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

28

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

109-116

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Diabetic neuropathies: a statement by the American Diabetes Association

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Classification, differential diagnosis, and staging of diabetic peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Neuropathy is associated with depression independently of health-related quality of life in Japanese patients with diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Sleep impairment in patients with painful diabetic peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Standards of medical care in diabetes--2009.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Placebo response in neuropathic pain trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03152.X

21 January 2018

Treatment of diabetic neuropathy and neuropathic pain: how far have we come?

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.2337/DC08-S263

Identifiers

10.1111/J.1464-5491.2010.03152.X

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21166852

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48326604&oldid=2044744020"